Accelerating Medicines Partnership® Heart Failure Program (AMP® HF)
What is the goal of the AMP HF?
More than 6 million adults in the United States have heart failure, a condition that develops when the heart cannot pump enough blood to meet the body's needs. About half of those people have heart failure with preserved ejection fraction (HFpEF, pronounced "heff-peff"). HFpEF develops when the left ventricle of the heart does not relax and refill normally between heartbeats. This is different from heart failure with reduced ejection fraction (HFrEF), which is when the heart cannot pump strongly enough to push blood throughout the body.
HFpEF is a high priority for the NHLBI because there are few effective treatments. Many treatments that work for HFrEF have not been effective in HFpEF.
The goal of the AMP HF program is to expand knowledge about HFpEF that may lead to better treatment options. Specifically, AMP HF aims to:
- Describe different subtypes of HFpEF, known as endotypes.
- Create a database of HFpEF patients and their health records so researchers can share data.
- Use data about different HFpEF types to find new ways to treat it.
- Develop a master study protocol for testing treatments.
AT A GLANCE
- AMP HF is harnessing the power of private-public partnerships to understand HFpEF.
- AMP HF analyzes HFpEF patient data to identify subtypes of HFpEF and to help find treatments that are tailored to individual patients.
- The data source for the AMP HF project is HeartShare — an NHLBI study for large-scale analysis of phenotypic data, images, and omics.
Why is the AMP HF program important?
HFpEF is often deadly. Just 35% to 40% of people diagnosed with it survive past 5 years. People who live with HFpEF experience a reduced quality of life. Over time it becomes harder and harder to do the tasks of daily living.
The AMP HF project is designed to improve the outlook for people with HFpEF through precision medicine — more individualized treatments based on specific types of HFpEF.
The NHLBI welcomes researchers to use the valuable resources collected through the AMP HF program. AMP HF data will become available in BioData Catalyst. BioData Catalyst is the NHLBI's cloud-based computing resource, which gives researchers secure access to data and images.
How does the AMP HF program work?
AMP HF is a public-private partnership between the Foundation for the National Institutes of Health (FNIH) and the NHLBI. Other partners include the U.S. Food and Drug Administration (FDA), biotech and pharmaceutical companies, patient advocacy groups, and nonprofit and professional organizations, such as the American Heart Association.
AMP HF uses a large set of data and specimens contributed by people who have HFpEF. The data and samples are collected through the NHLBI-supported HeartShare research program. HeartShare operates a data translation center and six clinical research centers. The data translation center is a hub for curating existing clinical data, images, and multi-omics and for prospectively collecting data and images.
Participants with and without HFpEF can enroll in the HeartShare registry. They complete surveys and provide health records for research use. The HeartShare clinical study includes a collection of prospective data from comprehensive testing (deep phenotyping). The testing uses cutting-edge technologies, including digital measurements, imaging studies, , and artificial intelligence. Deep phenotyping data can serve as a basis for defining HFpEF endotypes. The study investigators plan to enroll 1,000 participants (750 who have HFpEF and 250 without HFpEF).
In addition, scientists may contribute data or initiate ancillary studies in AMP HF.
The data from all the sources — prior studies, the registry, the HeartShare clinical study, contributed data — are combined and standardized. The AMP HF collaborators plan to analyze the HeartShare data to define different subtypes of HFpEF. Then researchers will explore how to treat each subtype with more precision.
More Information
-
Accelerating Medicines Partnership® Heart Failure Program (AMP® HF)
Who are the current AMP HF partners?
The following private-sector organizations are collaborating in AMP HF:
- American Heart Association
- American Society of Echocardiography
- Anumana
- Bayer US
- Cytokinetics, Inc.
- Ionis Pharmaceuticals, Inc.
- Novartis Institutes for BioMedical Research
- Ultromics Ltd.
The FDA and the NHLBI are public-sector partners in the AMP HF program.